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Introduction: Effective and efficient treatment for patients with metastatic 
colorectal cancer that can increase survival rate with limited side effects, is 
important. The purpose of this study was health technology assessment of 
Bevacizumab compare with combination of Bevacizumab with Erlotinib for 
treatment of patients with metastatic colorectal cancer. 
Methods and Results:In the present investigation first a systematic review on 
finding the studies was conducted. To reach this goal a comprehensive search in 
PubMed, Cochrane Library, Scopus, CRD, American Society of Clinical Oncology 
and European Society for Medical Oncology databases using the PICO based 
keywords was performed. Then, a retrieved study by means of two independent and 
expert reviewer during several steps (based on title, abstract and full-text, excluding 
of duplicated or unrelated cases) was chosen and non-qualified studies was exiled 
from the study. After that, 20 chosen randomized trial studies were evaluated by two 
experienced evaluators by Cochrane tool in terms of types of Bias. Eventually 
obtained data from the investigation was meta-analyzed by Revman5.3 software and 
safety, effectiveness and economical evaluation of the device were studied based on 
this data. To calculate the expenses of Bevacizumab and Erlotinib, Cost-
effectiveness Analysis with the perspective of the service provider in the public 
sector was performed. In total, three randomized controlled trials with 682 patients 
met the inclusion criteria.  The combination of Bevacizumab with Erlotinib for 
maintenance therapy of patients with metastatic colorectal cancer improved 
progression free survival by 0.19 and overall survival by 0.22. Degree three and four 
side effects of developed during treatment were limited and manageable. The 
combination of the two drugs was cost effective from the perspective of the service 
provider. 
Conclusions:Based on current evidence, prescribing the combination of 
Bevacizumab and Erlotinib in the maintenance treatment of metastatic colorectal 
cancer patients is cost effective from the perspective of service provider in the public 
sector, and the use of this combination in the health system is economically viable. 
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